Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mersana Therapeutics (MRSN) Misses Q2 EPS by $4.71
August 13, 2025 7:05 AM EDTMersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($4.87), $4.71 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.06 million versus the consensus estimate of $6.25 million.
For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.
... More